About the company

The biotechnology company Abviris Deutschland GmbH, based in Ahrensburg, Germany, is a pioneer in HPV serology, developing innovative, next generation products such as Prevo-Check® for early detection and post-treatment monitoring of HPV-induced tumours. Prevo-Check® makes it possible to easily detect pre-cancerous lesions from a drop of blood, thereby helping patients to improve their quality of life and chances of survival.

From a diagnostics point of view, it is irrelevant to detect the very common HPV infections but rather important to identify HPV-induced diseases.

The presence of increased HPV16 L1 antibodies is a highly specific indicator for altered cells in patients which have not been vaccinated against HPV. An elevated level of these antibodies is linked to the presence of pre-cancerous lesions or tumours.

While serological methods for the early detection of these HPV induced tumours did not exist in the past, Abviris Deutschland has developed a rapid test for the detection of HPV16 L1 antibodies in blood or serum.

The strong performance (clinical specificity ≥ 99.3%, clinical sensitivity ≥ 90%)  results from the use of HPV16-L1 epitope-specific antibodies. These antibodies are directed against a protein which is produced only by cells in which HPV16 has actively affected the cell division. This means that the antibody is only present if a sub clinical HPV16 infection has progressed to a cancer pre-stage or carcinoma.